Kali-Extracts, Inc. published the research report on the recent pilot treatment of Chronic Obstructive Pulmonary Disease in primates using an extract derived from KALY’s patented cannabis extraction process.
DALLAS, March 22, 2019 /PRNewswire/ -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today published the research report on the recent pilot treatment of Chronic Obstructive Pulmonary Disease (COPD) in primates using an extract derived from KALY’s patented cannabis extraction process. The report details the study method and the significance of the study. The report includes specific findings and due to the substantial findings, the report includes guidelines for next stage tests.
“These preliminary studies were designed to begin assessment of the relative efficacy of NCMB-1 compound on pulmonary of in the AGM previously treated to induce a fixed level of airway fibrosis. The overall results demonstrate that NCMB-1 improved airway function as measured by increased tidal volume, increased airway flow and hence decreased airway resistance and increased respiration rate.”
“Given the in vitro studies previously conducted in cultured human pulmonary epithelial cells, the role of anti-inflammatory agents and their genetic regulation are a clear target for the continued study of the AGM and pulmonary functional responses to NCMB-1.”
The full report can be read on the company’s website at www.kali-extracts.com.
KALY is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies. In addition developing pharmaceutical products internally and through partnerships, KALY is utilizing is patented cannabis extraction process to develop numerous wellness products both internally and through partnerships. The first revenue generating contracts signed in December of 2018 will be reflected in the company’s upcoming annual report.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company’s actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
+1-(214) 210-0459
View original content:http://www.prnewswire.com/news-releases/kaly-publishes-cannabis-extract-copd-treatment-study-report-300816903.html
SOURCE Kali, Inc.
Company Codes: OTC-PINK:KALY, OTC-QB:KALY, OTC-QX:KALY, OtherOTC:KALY
